Rapid Delivery Of Toxicological Study Material: The New Critical Path For Accelerating Biopharmaceutical Drug Development

The rapid transition from DNA to Investigational New Drug (IND) applications is shrinking the time available for crucial toxicology data generation. To address this challenge, faster delivery of materials for these studies is essential for timely IND submissions and accelerated clinical entry.

Accelerated toxicology material delivery significantly reduces the time it takes for a drug candidate to reach clinical trials.

In this webinar, we discuss key strategies and technologies that streamline analytical processes and material flows, enabling rapid toxicology material delivery. We introduce Lonza's new offerings, designed to reduce tox material generation time by up to 50%, effectively extending the toxicology study window by two months and preventing IND submission delays.

While standard toxicology study timelines typically range from four to five months, our approach shifts these studies earlier in the development process, mitigating potential bottlenecks and accelerating IND-enabling activities within Lonza programs.